MiRNA27a is a biomarker for predicting chemosensitivity and prognosis in metastatic or recurrent gastric cancer

Journal of Cellular Biochemistry

Volumn 115, Issue 3, 2014, Pages 549-556

  Huang, Dingzhi ^a   Wang, Haiyan ^a   Liu, Rui ^a   Li, Hongli ^a   Ge, Shaohua ^a   Bai, Ming ^a   Deng, Ting ^a   Yao, Guangyu ^a   Ba, Yi ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

CHEMOSENSITIVITY; FLUOROPYRIMIDINE; GASTRIC CANCER; PROGNOSIS; SERUM miRNA27a

Indexed keywords

BIOLOGICAL MARKER; FLUOROPYRIMIDINE; MICRORNA; MICRORNA 1; MICRORNA 27A; MICRORNA 34A; OXALIPLATIN; PACLITAXEL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CHEMOSENSITIVITY; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GASTRECTOMY; HUMAN; LIVER METASTASIS; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MIDDLE AGED; NEUTROPHIL; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER; TREATMENT RESPONSE; TUMOR DIFFERENTIATION; UPREGULATION;

CHEMOSENSITIVITY; FLUOROPYRIMIDINE; GASTRIC CANCER; PROGNOSIS; SERUM MIRNA27A;

AGED; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84892698096     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.24689     Document Type: Article

References (35)

1. Bartel DP,. 2004. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 116: 281-297.
2. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M, Croce CM,. 2004. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 101: 2999-3004.
3. Chan SH, Wu CW, Li AF, Chi CW, Lin WC,. 2008. miR-21 microRNA expression in human gastric carcinomas and its clinical association. Anticancer Res 28: 907-911.
4. Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, Barbisin M, Xu NL, Mahuvakar VR, Andersen MR, Lao KQ, Livak KJ, Guegler KJ,., 2005. Real-time quantification of microRNAs by stem-loo p RT-PCR. Nucleic Acids Res 33: e179.
5. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, Li Q, Li X, Wang W, Zhang Y, Wang J, Jiang X, Xiang Y, Xu C, Zheng P, Zhang J, Li R, Zhang H, Shang X, Gong T, Ning G, Wang J, Zen K, Zhang J, Zhang CY,. 2008. Characterization of microRNAs in serum: A novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18: 997-1006.
6. Choi YH, Oh SC, Kim JS, Nam SH, Kim BS, Cho SH, Chung IJ, Song EK, Yim CY, Baek JH, Jeung HC, Hong YS, Yang SH, Kang HJ,. 2012. A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: A Korean Cancer Study Group Protocol S T06-02. Cancer Chemother Pharmacol 70: 665-672.
7. D'Angelica M, Gonen M, Brennan MF, Turnbull AD, Bains M, Karpeh MS,. 2004. Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg 240: 808-816.
8. Ichikawa W, Sasaki Y,. 2006. Correlation between tumor response to first-line chemotherapy and prognosis in advanced gastric cancer patients. Ann Oncol 17: 1665-1672.
9. Jemal A, Siegel R, Xu J, Ward E,. 2010. Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
10. Ji Q, Hao X, Meng Y, Zhang M, Desano J, Fan D, Xu L,. 2008. Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC Cancer 8: 266.
11. Jiang J, Zheng X, Xu X, Zhou Q, Yan H, Zhang X, Lu B, Wu C, Ju J,. 2011. Prognostic significance of miR-181b and miR-21 in gastric cancer patients treated with S-1/Oxaliplatin or Doxifluridine/Oxaliplatin. PLoS ONE 6: e23271.
12. Jiang ZQ, Varadhachary G, Wang X, Kopetz S, Lee JE, Wang H, Shroff R, Katz M, Wolff RA, Fleming J, Overman MJ,. 2013. A retrospective study of ampullary adenocarcinomas: Overall survival and responsiveness to fluoropyrimidine-based chemotherapy. Ann Oncol 24: 2349-2353.
13. Jung MR, Park YK, Jeong O, Seon JW, Ryu SY, Kim DY, Kim YJ,. 2011. Elevated preoperative neutrophil to lymphocyte ratio predicts poor survival following resection in late stage gastric cancer. J Surg Oncol 104: 504-510.
14. Katada T, Ishiguro H, Kuwabara Y, Kimura M, Mitui A, Mori Y, Ogawa R, Harata K, Fujii Y,. 2009. microRNA expression profile in undifferentiated gastric cancer. Int J Oncol 34: 537-542.
15. Kim JG, Sohn SK, Chae YS, Song HS, Kwon KY, Do YR, Kim MK, Lee KH, Hyun MS, Ryoo HM, Bae SH, Park KU, Lee WS, Baek JH, Chung HY, Yu W,. 2008. Multicenter phase II study of docetaxel plus oxaliplatin combination chemotherapy in patients with advanced gastric cancer: Daegu Gyeongbuk Oncology Group. Br J Cancer 98: 542-546.
16. Kodera Y, Ito Y, Ohashi N, Nakayama G, Koike M, Fujiwara M, Nakao A,. 2011. Impact of clinical response to first-line chemotherapy on gastric cancer patients treated with second-line and third-line chemotherapy. Hepatogastroenterology 58: 1041-1045.
17. Kovalchuk O, Filkowski J, Meservy J, Ilnytskyy Y, Tryndyak VP, Chekhun VF, Pogribny IP,. 2008. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther 7: 2152-2159.
18. Liu T, Tang H, Lang Y, Liu M, Li X,. 2009. MicroRNA-27a functions as an oncogene in gastric adenocarcinoma by targeting prohibitin. Cancer Letters 273: 233-242.
19. Li X, Liu X, Xu W, Zhou P, Gao P, Jiang S, Peter E,., Lobie Zhu T,. 2013. c-MYC-regulated miR-23a/24-2/27a Cluster Promotes Mammary Carcinoma Cell Invasion and Hepatic Metastasis by Targeting Sprouty2. J Biol Chem 288: 18121-18133.
20. Kukreti H, Amuthavalli K, Harikumar A, Sathiyamoorthy S, Feng PZ, Anantharaj R, Tan SL, Lokireddy S, Bonala S, Sriram S, McFarlane C, Kambadur R, Sharma M,. 2013. Muscle-specific microRNA1 (miR1) targets heat shock protein 70 (HSP70) during dexamethasone-mediated atrophy. J Biol Chem 288: 6663-6678.
21. Li ZM, Hu S, Xiao L, Wang J, Cai J, Yu LL, Wang ZH,. 2010. Expression of microRNA 27a and its correlation with drug resistance in human ovarian cancer A2780/Taxol cells. Zhonghua Fu Chan Ke Za Zhi 45: 372-375.
22. Liu R, Zhang C, Hu Z, Li G, Wang C, Yang C, Huang D, Chen X, Zhang H, Zhuang R, Deng T, Liu H, Yin J, Wang S, Zen K, Ba Y, Zhang CY,. 2011. A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. Eur J Cancer 47: 784-791.
23. Liu K, Qian T, Tang L, Wang J, Yang H, Ren J,. 2012. Decreased expression of microRNA let-7i and its association with chemotherapeutic response in human gastric cancer. World J Surg Oncol 10: 225.
24. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M,. 2008. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105: 10513-10518.
25. Ng EK, Chong WW, Jin H, Lam EK, Shin VY, Yu J, Poon TC, Ng SS, Sung JJ,. 2009. Differential expression of microRNAs in plasma of patients with colorectal cancer: A potential marker for colorectal cancer screening. Gut 58: 1375-1381.
26. Petrie HT, Klassen LW, Kay HD,. 1985. Inhibition of human cytotoxic T lymphocyte activity in vitro by autologous peripheral blood granulocytes. J Immunol 134: 230-234.
27. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA,. 2006. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 Study Group. J Clin Oncol 24: 4991-4997.
28. Wanebo HJ, Kennedy BJ, Chmiel J, Jr., Steele G, Winchester D, Osteen R,. 1993. Cancer of the stomach. A patient care study by the American College of Surgeons. Ann Surg 218: 583-592.
29. Watanabe H, Okada M, Kaji Y, Satouchi M, Sato Y, Yamabe Y, Onaya H, Endo M, Sone M, Arai Y,. 2009. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 36: 2495-2501.
30. Yamanaka T, Matsumoto S, Teramukai S, Ishiwata R, Nagai Y, Fukushima M,. 2007. The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer. Oncology 73: 215-220.
31. Yang N, Kaur S, Volinia S, Greshock J, Lassus H, Hasegawa K, Liang S, Leminen A, Deng S, Smith L, Johnstone CN, Chen XM, Liu CG, Huang Q, Katsaros D, Calin GA, Weber BL, Butzow R, Croce CM, Coukos G, Zhang L,. 2008. MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res 68: 10307-10314.
32. Yoo CH, Noh SH, Shin DW, Choi SH, Min JS,. 2000. Recurrence following curative resection for gastric carcinoma. Br J Surg 87: 236-242.
33. Zhang H, Li M, Han Y, Hong L, Gong T, Sun L, Zheng X,. 2010. Down-regulation of miR-27a might reverse multidrug resistance of esophageal squamous cell carcinoma. Dig Dis Sci 55: 2545-2551.
34. Zhao X, Yang L, Hu J,. 2011. Down-regulation of miR-27a might inhibit proliferation and drug resistance of gastric cancer cells. J Exp Clin Cancer Res 30: 55.
35. Zhu H, Wu H, Liu X, Evans BR, Medina DJ, Liu CG, Yang JM,. 2008. Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem Pharmacol 76: 582-588.